key: cord-0713743-g0za5fqi
authors: Nogues, Xavier; Ovejero, Diana; Pineda-Moncusí, Marta; Bouillon, Roger; Arenas, Dolors; Pascual, Julio; Ribes, Anna; Guerri-Fernandez, Robert; Villar-Garcia, Judit; Rial, Abora; Gimenez-Argente, Carme; Cos, Maria Lourdes; Rodriguez-Morera, Jaime; Campodarve, Isabel; Quesada-Gomez, José Manuel; Garcia-Giralt, Natalia
title: Calcifediol treatment and COVID-19-related outcomes
date: 2021-06-07
journal: J Clin Endocrinol Metab
DOI: 10.1210/clinem/dgab405
sha: 783d93d8deb4f27574e977217a7b0a8f0f8cd9c1
doc_id: 713743
cord_uid: g0za5fqi

CONTEXT: COVID-19 is a major health problem because of saturation of intensive care units (ICU) and mortality. Vitamin D has emerged as a potential treatment able to reduce the disease severity. OBJECTIVE: To elucidate the effect of calcifediol [25OHD3] treatment on COVID-19-related outcomes. DESIGN: Observational cohort study from March to May, 2020. SETTING: Patients admitted to COVID-19 wards of Hospital del Mar, Barcelona, Spain. PATIENTS: A total of 930 patients with COVID-19 were included. Ninety-two were excluded due to previous calcifediol intake. INTERVENTION: Of the remaining 838, a total of 447 received calcifediol (532ug on day one plus 266ug on day 3, 7, 15, and 30) whereas 391 were not treated at the time of hospital admission (Intention-to-Treat). Of the latter, 53 patients were treated later during ICU admission and were allocated in the treated group in a second analysis. In healthy subjects, calcifediol is about 3.2-fold more potent on a weight basis than cholecalciferol. MAIN OUTCOME MEASURES: ICU admission and mortality. RESULTS: ICU assistance was required by 102 (12.2%) participants. Out of 447 patients treated with calcifediol at admission, 20 (4.5%) required ICU, compared to 82 (21%) out of 391 non-treated (p-value<0.0001). Logistic regression of calcifediol treatment on ICU admission, adjusted by age, gender, linearized 25OHD levels at baseline, and comorbidities showed that treated patients had a reduced risk to require ICU (OR 0.13 [95% CI 0.07;0.23]). Overall mortality was 10%. In the Intention-to-Treat analysis, 21 (4.7%) out of 447 patients treated with calcifediol at admission died compared to 62 patients (15.9%) out of 391 non-treated (p=0.0001). Adjusted results showed a reduced mortality risk with an OR 0.21 [95% CI 0.10; 0.43]). In the second analysis, the obtained OR was 0.52 [95% CI 0.27;0.99]. CONCLUSIONS: In patients hospitalized with COVID-19, calcifediol treatment significantly reduced ICU admission and mortality.

and dexamethasone, or other corticosteroids, the only therapy that has been shown to reduce mortality so far in patients requiring mechanical ventilation or high-flow oxygen (5) . More recently, the FDA has approved by Emergency Use Authorization of baricitinib in combination with remdesivir in patients requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (6) , as well as the neutralizing antibody bamlanivimab (LY-CoV555) (7) Adequate vitamin D status has emerged as a potentially preventing factor for COVID-19 progression and mortality (8, 9) . Vitamin D endocrine system's (VDES) protective effects are supported by studies that point to a role of the hormone in innate and acquired immunity modulation, autophagy induction, and synthesis of reactive oxygen intermediates (10, 11) . In addition, vitamin D is known to be involved in the induction of antimicrobial peptides in response to both viral and bacterial infections (12) . A systematic review and meta-analysis from randomized controlled trials including more than 11 ,000 participants before the onset of COVID-19, showed protective effects of daily or weekly vitamin D administration on the risk of acute respiratory tract infection (13) . Many data indicate that vitamin D deficiency, which is common among critically ill patients, is associated with longer hospital and ICU length of stay, lung and other organ injury, prolonged mechanical ventilation, and death (14) .

A c c e p t e d M a n u s c r i p t 7 Recent studies suggested that vitamin D supplementation might reduce the risk of influenza and SARS-CoV-2-related infections and deaths by decreasing pro-inflammatory cytokine production, thereby, diminishing the risk of developing a cytokine storm, which ultimately leads to ARDS development (15) . A 2017 meta-analysis of data from 25 randomised controlled trials (RCTs) of vitamin D supplementation for the prevention of acute respiratory infections revealed a protective effect of this intervention, although the risk reduction was small. Protection was associated with administration of daily doses of 400-1000 IU for up to 12 months (16) .

Considering the aforementioned data, we evaluated the effect of calcifediol treatment and baseline 25OHD serum levels on COVID-19-related severe outcomes: ICU admission and mortality rate among patients hospitalized for COVID-19 in a population-based study on patients admitted to COVID-19 wards in Hospital del Mar, Barcelona, Spain.

Clinical data from patients with COVID-19, hospitalized randomly at one of the eight COVID-19 Units 

The outcomes of the study were admission into ICU (yes/no) and mortality (yes/no). The effect of calcifediol administration was studied in a prospective open label study. The consequences of baseline vitamin D status were studied in a subset of 678 patients for whom baseline serum 25OHD concentrations were measured.

Serum 25OHD levels Serum levels of 25OHD were measured at baseline through competitive immunoluminometric direct assay with direct-coated magnetic microparticles (coefficient of variation<10%) (Elecsys 25OHD total II, model 07028148190; Cobas e801 system, Roche Diagnostics GmbH, Mannheim, Germany).

Obtained baseline levels were linearized using the decimal logarithm (logarithm with base 10 or log10) to fit the multivariate regression analysis. Moreover, participants were classified according their 25OHD levels: patients with a serum concentration below 20 ng/ml were considered to be vitamin D deficient, while those with ≥20 ng/mL were considered to be vitamin D replete (17, 18) .

A c c e p t e d M a n u s c r i p t 

A total of 832 participants were included in the intention-to-treat analysis (ITT analysis). Of them, 447 patients were treated with calcifediol at admission and 391 were not treated. Fifty-three patients of this non-treated group started calcifediol during ICU admission. These patients were allocated in the treated group in a second analysis ( Figure 1 ). Patient characteristics, stratified by calcifediol treatment at admission (ITT) are reported in Table 1A . Significant differences were found in baseline 25OHD

A c c e p t e d M a n u s c r i p t 11 levels between groups where the treated group had a median higher than the non-treated group (13 into the ICU (34) . This life-threatening condition is the consequence of an inflammatory and diffuse alveolar injury of acute onset, which leads to bilateral lung infiltration and severe hypoxemia. The pathogenesis of ARDS is closely linked to an exacerbated pro-inflammatory cytokine response of the A c c e p t e d M a n u s c r i p t 15 host (35) , and it is precisely in this setting where we speculate that vitamin D exerted its main beneficial effects. The adaptive immune system can be modulated by 1,25(OH) 2 D, most importantly by modifying the phenotype of dendritic cells (responsible for antigen presentation to T cells) leading to a decrease in pro-inflammatory T cells subtypes proliferation, while enhancing the production of regulatory T cells (36) . Pro-inflammatory cytokine release in macrophages is also decreased by 1,25(OH) 2 D (37). Ultimately these effects are thought to curb the inflammatory cascade that leads to the cytokine and chemokine storm associated with the pathogenesis of ARDS.

There might be other mechanisms by which vitamin D might protect against ARDS (38) . It downregulates the renin-angiotensin system (RAS), a pro-inflammatory endocrine axis implicated in ARDS pathogenesis through the decrease of renin activity and by increasing angiotensin converting enzyme 2 (ACE2) and controlling the alteration of the coagulation cascade. Intra-alveolar fibrin clots are particularly typical in coronavirus-provoked ARDS, and in addition to its inhibitory effects on RAS, several in vitro studies also suggest that 1,25(OH) 2 D displays direct anti-thrombotic effects. Finally, vitamin D appears to also play a role in the maintenance and repair of the respiratory epithelium, thus, potentially helping in the prevention and resolution of acute lung injury.

The study also confirmed that age and obesity were additional risk factors. Indeed, both factors have been linked to COVID-19 severity and poor outcomes in multiple studies and at the same time are well-established risk factors for vitamin D deficiency (39) . Our analysis also included a logistic regression analysis eliminating the potential confounding effect of age and obesity.

There are several limitations in the present study. First, it was not placebo controlled and no electronic/statistical randomization was performed and hence, it cannot be considered as a randomized controlled trial. However, since incoming patients were assigned to a ward based on bed availability and therefore, were not selected, we can consider the effect of calcifediol close to an open label clinical study performed in real life conditions. Second, statistical differences in baseline 25OHD levels were found between treated and non-treated patients in the ITT analysis, even though these differences cannot be considered clinically relevant. Of note, all analyses were adjusted by these 25OHD levels as well as other confounder variables. Another limitation is that serum 25OHD was not measured during follow-up. No dose response curve was tested, so that we cannot define the minimal required dose and there was also no comparison with the more commonly used forms of vitamin D.

A c c e p t e d M a n u s c r i p t 16 However, considering the administered doses and the drug's pharmacokinetic profile, we assume it replenished 25OHD deposits in all treated patients. Finally, severity scales were not analyzed.

In spite of its weaknesses, the study was adequately powered to detect possible effects on the essential hard end points of ICU admission and mortality.

In summary, calcifediol administered shortly after hospitalization markedly reduced the requirement for ICU admission and decreased mortality by more than 50%. Moreover, baseline 25OHD levels A c c e p t e d M a n u s c r i p t 26 

Clinical Characteristics of Coronavirus Disease 2019 in China

Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments

Epidemiology and public health response in early phase of COVID-19 pandemic

Remdesivir for the Treatment of Covid-19 -Final Report

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply

The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality

Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results

Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory. JBMR Plus

Vitamin D and tuberculosis: where next?

Vitamin D attenuates rhinovirus-induced expression of intercellular adhesion molecule-1 (ICAM-1) and platelet-activating factor receptor (PAFR) in respiratory epithelial cells

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data

Vitamin D deficiency and supplementation in critical illnessthe known knowns and known unknowns

Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths

Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials

Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions

25(OH)D deficiency 2.0: an update on the current status worldwide

Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study

Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial

Vitamin D and survival in COVID-19 patients: A quasi-experimental study

Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests

High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study

Is calcifediol better than cholecalciferol for vitamin D supplementation?

Pharmacokinetics of oral vitamin D(3) and calcifediol

Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID

Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection

Vitamin D Deficiency and Outcome of COVID-19 Patients

Does Serum Vitamin D Level Affect COVID-19 Infection and Its Severity?-A Case-Control Study

Original publication: Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity

Vitamin D status and outcomes for hospitalised older patients with COVID-19

Vitamin D and COVID-19 infection and mortality in UK Biobank

Impact of Vitamin D Deficiency on COVID-19-A Prospective Analysis from the CovILD Registry

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists

25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation

Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166

Covid-19: risk factors for severe disease and death